HAVCR2 expression was higher in most tumors, including glioblastoma and low-grade glioma (GBMLGG), lung adenocarcinoma (LUAD), prostatic adenocarcinoma (PRAD), and sarcoma (SARC) (70). This evidence concerns the gene HAVCR2 and prostate adenocarcinoma.